Symtuza FDA Approval History
FDA Approved: Yes (First approved July 17, 2018)
Brand name: Symtuza
Generic name: cobicistat, darunavir, emtricitabine and tenofovir alafenamide
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: HIV Infection
Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.
Development timeline for Symtuza
Symtuza (cobicistat, darunavir, emtricitabine and tenofovir alafenamide) Consumer information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.